87 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals, Inc.
8 Aug 24
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results
4:10pm
(international) and refer to Conference ID CRNXQ2. To access the webcast, click here. Following the live event, a replay of the call will be available
424B5
CRNX
Crinetics Pharmaceuticals, Inc.
21 Jun 24
Prospectus supplement for primary offering
6:11pm
is owned by the users of its regulated subsidiaries. Access to the DTC system is also available to others, which we sometimes refer to as indirect
8-K
EX-1.1
CRNX
Crinetics Pharmaceuticals, Inc.
21 Jun 24
Other Events
5:24pm
in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific … and to the protection of such IT Systems and Sensitive Data from unauthorized use, access, misappropriation or modification. The Company and its subsidiaries have
S-3ASR
CRNX
Crinetics Pharmaceuticals, Inc.
21 Jun 24
Automatic shelf registration
4:45pm
Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries. Access to the DTC system
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals, Inc.
3 Jun 24
Regulation FD Disclosure
4:35pm
by an operator OR click the Call me™ link for instant telephone access to the event.
Call me™: https://emportal.ink/3K5zWA3
Webcast: https://viavid.webcasts.com
8-K
EX-99.1
lvo08
9 May 24
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results
4:12pm
DEFA14A
dcgc0sggare lw
25 Apr 24
Additional proxy soliciting materials
4:48pm
8-K
EX-99.2
um9f6lqys4ylp
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
7pixl65612id6z6z
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.1
9d81jzx 2221o4bw
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.1
7h65vodzmkqv78kea
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-10.1
s7rj3kq2ytc
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-10.2
6wxx exan0ln9
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-99.1
xj1rl413nfq3cj2mhror
28 Feb 24
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
awep 13uz
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.1
bzqjkh9dg jcx13s
8 Jan 24
Regulation FD Disclosure
8:03am